64,416 IDEXX Laboratories, Inc. $IDXX Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,492 shares of the company’s stock after selling 64,416 shares during the period. Vontobel Holding Ltd.’s holdings in IDEXX Laboratories were worth $66,575,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Pension & Wealth Management Advisors Inc. acquired a new stake in IDEXX Laboratories during the third quarter worth approximately $29,000. Howard Capital Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth $1,249,000. V Square Quantitative Management LLC raised its holdings in IDEXX Laboratories by 4.9% in the 3rd quarter. V Square Quantitative Management LLC now owns 2,171 shares of the company’s stock valued at $1,134,000 after acquiring an additional 102 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in IDEXX Laboratories by 39.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 256,362 shares of the company’s stock valued at $133,870,000 after acquiring an additional 73,129 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $538,000. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.79% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a research report on Friday. They set a “buy” rating and a $740.00 target price for the company. Citigroup raised their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded up $13.18 during trading hours on Friday, hitting $560.36. 708,811 shares of the stock were exchanged, compared to its average volume of 531,547. The company’s fifty day simple moving average is $534.22 and its two-hundred day simple moving average is $551.84. The company has a market cap of $44.15 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.92 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the previous year, the business earned $3.50 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.80 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.